| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/06/2004 | CA2085201C New pyridyl derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| 07/01/2004 | WO2004055033A1 Adenosine derivative in polymorph iv form |
| 07/01/2004 | WO2004055032A1 Adenosine derivative in polymorph v form |
| 07/01/2004 | WO2004054979A1 Jnk inhibitors |
| 07/01/2004 | WO2004054616A1 Antagonist and agonist binding to strong binding site of chemokine receptor |
| 07/01/2004 | WO2004054604A1 Medicinal composition for treating ischemic cardiac failure |
| 07/01/2004 | WO2004054594A1 Cell death inhibitor |
| 07/01/2004 | WO2004054590A1 New ginsenoside used in antitumor agents |
| 07/01/2004 | WO2004054577A1 Alpha-2-delta ligands to treat ocd and related diseases |
| 07/01/2004 | WO2004054575A1 Combinations of valsartan with cox-2 inhibitors |
| 07/01/2004 | WO2004054563A1 Alpha-2-delta ligand for the treatment of sexual dysfunction |
| 07/01/2004 | WO2004054559A1 Alpha2delta ligands for different pharmaceutical uses |
| 07/01/2004 | WO2004022540A3 Pyridazinone and pyridone derivatives as adenosine antagonists |
| 07/01/2004 | WO2004018058A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004017906A3 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 07/01/2004 | WO2004016612A3 New purine derivatives |
| 07/01/2004 | WO2004014298A3 Composition and method for lowering cholesterol |
| 07/01/2004 | WO2004006865A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004002420A3 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 07/01/2004 | WO2003103608A3 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 07/01/2004 | WO2003100435A3 Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2) |
| 07/01/2004 | WO2003093297A3 Protein kinase modulators and methods of use |
| 07/01/2004 | WO2003092605A3 Protease inhibitors |
| 07/01/2004 | WO2003086325A3 Cyanamides useful as reversible inhibitors of cysteine proteases |
| 07/01/2004 | WO2003045369A9 Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses |
| 07/01/2004 | WO2003040366A3 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 07/01/2004 | WO2002100341A3 Compounds for the treatment of metabolic disorders |
| 07/01/2004 | US20040127735 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral |
| 07/01/2004 | US20040127712 Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors |
| 07/01/2004 | US20040127707 Novel phthalazinones |
| 07/01/2004 | US20040127705 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 07/01/2004 | US20040127686 Signal transduction regulator binding protein for identifying modulators for prevention and treatment of cardiomyopic hypertrophy, heart failure and diabetes; drug screening |
| 07/01/2004 | US20040127576 Estrogen receptor modulators |
| 07/01/2004 | US20040127552 Benzoaxathiepin derivatives and their use as medicines |
| 07/01/2004 | US20040127544 Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127542 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127539 Antiangiogenic combination therapy for the treatment of cancer |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127528 Metalloproteinase inhibitors |
| 07/01/2004 | US20040127527 Large conductance calcium-activated k channel opener |
| 07/01/2004 | US20040127517 For therapy of treat atherosclerosis, autoimmune diseases, multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases, idiopathic pulmonary fibrosis, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout |
| 07/01/2004 | US20040127513 For prophylaxis and therapy of chronic or acute inflammatory or autoimmune diseases, those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease |
| 07/01/2004 | US20040127508 Substituted pyrazolopyrimidines and thiazolopyrimidines |
| 07/01/2004 | US20040127496 Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
| 07/01/2004 | US20040127492 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| 07/01/2004 | US20040127474 Contacting the cell with a ptc agonist in a sufficient amount to inhibit the altered growth state, wherein the ptc agonist is a organic molecule having a molecular weight less than about 750 amu for inhibiting an altered growth state of a cell |
| 07/01/2004 | US20040127468 phosphatidic acid decreases apoptosis induced by the sudden withdrawal of NGF and serum (trophic withdrawal), rotenone, and glutamate |
| 07/01/2004 | US20040127462 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae |
| 07/01/2004 | US20040127452 C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040126878 Method for the preparation of immunologically inert amniotic membranes |
| 07/01/2004 | US20040126863 Comprises amino acid sequences for use in identifying modulators for diagnosis and treatment of respiratory and diabetes-induced peripheral vascular diseases; mimetics |
| 07/01/2004 | US20040126825 Using a compounds ability to decrease integrin activation as a diagnostic tool for the identification of antagonistic modulators of neovascularizaton; antitumor/antiproliferative agents |
| 07/01/2004 | US20040126801 Novel polynucleotides and encoded polypeptides |
| 07/01/2004 | US20040126799 First nucleotide sequence comprises adenine residue at position 1033 or equivalent; reducing disease treatment side effects |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126758 homologous to the known fibrinogen derived haptotactic peptides; shown to elicit activity from fibroblasts, endothelial and smooth muscle cells; for wound healing and enhancing osteogenesis/angiogenesis in vivo with/without medical implant |
| 07/01/2004 | US20040126423 Pharmaceutical formulation |
| 07/01/2004 | US20040126367 Oxidation resistance; storage at low temperature; overcoated with liposomes from soybean lecithin |
| 07/01/2004 | US20040126359 Modulate lymphocyte activation; cell proliferation; apoptosis; signal transduction |
| 07/01/2004 | US20040126356 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 07/01/2004 | DE10257785A1 Isophthalsäurederivate Isophthalic acid derivatives |
| 07/01/2004 | CA2509618A1 Pharmaceutical compositions for treating non-ischemic heart failure |
| 07/01/2004 | CA2509611A1 Method of treatment for sexual dysfunction |
| 07/01/2004 | CA2509600A1 Pharmaceutical uses for alpha2delta ligands |
| 07/01/2004 | CA2506809A1 Combinations of valsartan with cox-2 inhibitors |
| 06/30/2004 | EP1433786A1 Benzoxazole compound and pharmaceutical composition containing the compound |
| 06/30/2004 | EP1433783A2 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 06/30/2004 | EP1433780A1 19-nor-vitamin D3 compounds with calcemic activity |
| 06/30/2004 | EP1433500A2 Blood fluidity-improving health foods |
| 06/30/2004 | EP1432803A2 Fragments of the human zn-alpha2-glycoprotein and their use in methods of treatment of obesity |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432736A2 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
| 06/30/2004 | EP1432730A2 Glucagon-like peptide-1 analogs |
| 06/30/2004 | EP1432723A2 Modulation of the expression of genes dependent on stat-1 |
| 06/30/2004 | EP1432715A2 Pyrimidine derivatives |
| 06/30/2004 | EP1432714A2 Chemical compounds |
| 06/30/2004 | EP1432711A1 1,6-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432710A1 1, 8-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432708A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| 06/30/2004 | EP1432706A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| 06/30/2004 | EP1432703A1 Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| 06/30/2004 | EP1432702A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 06/30/2004 | EP1432701A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract |
| 06/30/2004 | EP1432700A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 06/30/2004 | EP1432699A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432698A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| 06/30/2004 | EP1432697A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432691A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 06/30/2004 | EP1432690A2 Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence |
| 06/30/2004 | EP1432687A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 06/30/2004 | EP1432683A1 Novel crystalline polymorphic forms of lercanidipine hydrochloride and processes for their preparation |
| 06/30/2004 | EP1432681A1 Pseudopolymorphic forms of carvedilol |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432527A2 Biological control of nanoparticles |
| 06/30/2004 | EP1432460A2 Bioactive materials for aneurysm repair |
| 06/30/2004 | EP1432454A2 Methods for sterilizing preparations containing albumin |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432443A2 Angiotensin peptide-carrier conjugates and uses thereof |
| 06/30/2004 | EP1432437A2 Human tissue urokinase type plasminogen activator formulation |